BioSpace News Archive

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd American Society of Hematology (ASH) Annual Meeting.

Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced efficacy data from a study of JBI-802, its novel dual inhibitor of LSD1-HDAC6, in multiple acute myeloid leukemia (AML) models, and the identificat

Capital raised in 2020 increases by over 20% YoY. Investments in Israeli companies more than tripled in six years Israel records a sharp rise in high-tech investments compared with Europe, Asia, and America. Hundreds of Israeli technological innovation solutions implemented worldwide during COVID-19

Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at 3 p.m. (Pacific Time) . The meeting details and instructions on how to access the virtual meeting are provided below:

Eurofins announces that its FDA-authorized At-Home COVID-19 Nasal PCR Test is now being covered by Medicare, Medicaid and commercial insurance providers

“Lab at your fingertip” technology requiring no additional equipment with pending EUA application delivers 100% sensitivity and 100% specificity in BEI study

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC® programs

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the closing of its initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock,

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting.

No severe vaso-occlusive events (VOEs) reported through 24 months of follow-up in Group C patients who had a history of at least four severe VOEs and at least six months of follow-up (n=19)